Results 91 to 100 of about 3,679,356 (272)
Blood Cancer Journal, 2021 Background Hypomethylating agents (HMA) remain the backbone for treating higher risk myelodysplastic syndromes (MDS) patients (pts) with less than 20% of pts achieving complete response (CR) and median overall survival (OS) of 12-18 months.
R. Komrokji +8 more
semanticscholar +1 more source
Advanced Science, EarlyView.Repeated disuse imprints a molecular memory in skeletal muscle, conferring transcriptional resilience in young adults but exaggerated susceptibility in aged muscle, driven by epigenetic regulation of aerobic metabolism, mitochondrial and NAD+ pathways.
Daniel C. Turner +14 more
wiley +1 more source
Nature Communications, 2023 Hypomethylating agents, such as 5-Azacytidine (5-AZA), are standard of care for patients with myelodysplastic and myeloid malignancies, however response rates are limited and risk of relapses high.
Qingyu Xu +31 more
doaj +1 more source
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. [PDF]
, 2019 Introduction: Acute myeloid leukemia (AML) remains a disease with high mortality, especially for older patients and those with relapsed/refractory (R/R) disease.
Galkin, Maria, Jonas, Brian A
core +1 more source
Protein glycosylation in sugar beet cell line can be influenced by DNA hyper- and hypomethylating agents [PDF]
, 2012 Protein glycosylation is a co- and post-translational modification that influences protein function, stability and localization. Changes in glycoprotein pattern during differentiation/dedifferentiation events exist in animal cells and DNA methylation ...
Dubravko Pavoković +1 more
core +2 more sources
Advanced Science, EarlyView.ABSTRACT Mass cytometry is optimal for acute leukemia immune checkpoint profiling. However, current commercial metal‐chelating polymer (MCP) metal tags limit its sensitivity due to low metal loading capacity. We report a novel synthetic strategy employing antibody‐conjugated gold or platinum nanoparticles (AuNP/PtNP) for high‐dimensional single‐cell ...
Zhizhou Liu +8 more
wiley +1 more source
Low-intensity regimens standard-intensity induction strategies in acute myeloid leukemia
Therapeutic Advances in Hematology, 2020 Treatment options for elderly patients with acute myeloid leukemia (AML) remain limited. In this age group, AML is frequently associated with poor-risk features, while patients’ present comorbidities and reduced functional reserves.
Norbert Vey
doaj +1 more source
Endocrine Oncology, 2023 Downregulation of tumor suppression genes by DNA hypermethylation has been proposed as a potential cause of neuroendocrine neoplasm (NEN) formation. In this report, we present a patient simultaneously diagnosed with acute myeloid leukemia (AML) and a ...
Syed Ehsanullah, Nikolaos A Trikalinos
doaj +1 more source
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway [PDF]
, 2018 Mutations in KIT and TET2 are associated with myeloid malignancies. We show that loss of TET2-induced PI3K activation and -increased proliferation is rescued by targeting the p110α/δ subunits of PI3K.
Gerbaulet, A +13 more
core +1 more source
Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials
iNew Medicine, EarlyView.ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong +5 more
wiley +1 more source